SG10201800851XA - Cytotoxicity-inducing therapeutic agent - Google Patents

Cytotoxicity-inducing therapeutic agent

Info

Publication number
SG10201800851XA
SG10201800851XA SG10201800851XA SG10201800851XA SG10201800851XA SG 10201800851X A SG10201800851X A SG 10201800851XA SG 10201800851X A SG10201800851X A SG 10201800851XA SG 10201800851X A SG10201800851X A SG 10201800851XA SG 10201800851X A SG10201800851X A SG 10201800851XA
Authority
SG
Singapore
Prior art keywords
cytotoxicity
therapeutic agent
inducing therapeutic
inducing
agent
Prior art date
Application number
SG10201800851XA
Inventor
Junichi Nezu
Atsushi Narita
Takahiro Ishiguro
Mika Sakurai
Hirotake Shiraiwa
Naoka Hironiwa
Tomoyuki Igawa
Yumiko Kawai
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2014197315 priority Critical
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201800851XA publication Critical patent/SG10201800851XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG10201800851XA 2014-09-26 2015-09-25 Cytotoxicity-inducing therapeutic agent SG10201800851XA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014197315 2014-09-26

Publications (1)

Publication Number Publication Date
SG10201800851XA true SG10201800851XA (en) 2018-03-28

Family

ID=55581241

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201800851XA SG10201800851XA (en) 2014-09-26 2015-09-25 Cytotoxicity-inducing therapeutic agent
SG11201701119RA SG11201701119RA (en) 2014-09-26 2015-09-25 Cytotoxicity-inducing therapeutic agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701119RA SG11201701119RA (en) 2014-09-26 2015-09-25 Cytotoxicity-inducing therapeutic agent

Country Status (19)

Country Link
US (2) US9975966B2 (en)
EP (1) EP3199628A4 (en)
JP (3) JP5941230B1 (en)
KR (2) KR101777077B1 (en)
CN (1) CN107002068A (en)
AU (1) AU2015322543A1 (en)
BR (1) BR112017006061A2 (en)
CA (1) CA2960650A1 (en)
CL (1) CL2017000704A1 (en)
CR (1) CR20170124A (en)
EA (1) EA201790674A1 (en)
IL (1) IL250685D0 (en)
MX (1) MX2017003503A (en)
PE (1) PE20170704A1 (en)
PH (1) PH12017500507A1 (en)
RU (1) RU2017113731A3 (en)
SG (2) SG10201800851XA (en)
TW (2) TW201730209A (en)
WO (1) WO2016047722A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR20150064068A (en) 2012-10-08 2015-06-10 로슈 글리카트 아게 FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE
AU2014222779B2 (en) 2013-02-26 2018-08-30 Roche Glycart Ag Bispecific T cell activating antigen binding molecules
WO2015050158A1 (en) * 2013-10-01 2015-04-09 国立大学法人三重大学 T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
SG10201800250XA (en) 2013-12-17 2018-02-27 Genentech Inc Anti-cd3 antibodies and methods of use
CN106661120A (en) 2014-08-04 2017-05-10 豪夫迈·罗氏有限公司 Bispecific t cell activating antigen binding molecules
SG10201800851XA (en) 2014-09-26 2018-03-28 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
TW201712036A (en) 2015-06-16 2017-04-01 建南德克公司 Humanized and affinity matured antibodies to FcRH5 and methods of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
JPWO2018038046A1 (en) 2016-08-22 2019-06-20 中外製薬株式会社 Genetically modified non-human animal expressing human GPC3 polypeptide

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
JPH0159878B2 (en) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491D0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
AU649952B2 (en) 1989-12-11 1994-06-09 Immunomedics Inc. Method for antibody targeting of diagnostic or therapeutic agents
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
TW212184B (en) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH04228089A (en) 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd Agent for treatment and prevention of hypercalcemia
JPH05184383A (en) 1990-06-19 1993-07-27 Dainabotsuto Kk Bispecific antibody
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69229477D1 (en) 1991-09-23 1999-07-29 Cambridge Antibody Tech Methods for producing humanized antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH05199894A (en) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd Bi-specific antibody and antibody-containing medicine
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69229482D1 (en) 1991-04-25 1999-07-29 Chugai Pharmaceutical Co Ltd Recombinant human antibodies against the human interleukin 6 receptor
JPH04336051A (en) 1991-05-10 1992-11-24 Toshiba Corp Ultrasonic diagnosing device
JPH05304992A (en) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd Hybridoma-monoclonal antibody and medicine containing antibody
ES2341666T3 (en) 1991-12-02 2010-06-24 Medical Research Council Production of authortic bodies of repertories of antique rpos segments expressed on the fagos surface.
DE69233528D1 (en) 1991-11-25 2005-07-14 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (en) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd Antibody enzyme immunoassay
JPH05213775A (en) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Bfa antibody
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
EP0640094A1 (en) 1992-04-24 1995-03-01 Board Of Regents The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ZA9306260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995015393A1 (en) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Novel expression screening vector
JP3485266B2 (en) 1994-05-20 2004-01-13 松下電器産業株式会社 Processor
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
HU223602B1 (en) 1994-10-07 2004-10-28 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for treating chronic rheumatoid arthritis, comprising an antibody against IL-6 receptor
HU225392B1 (en) 1994-10-21 2006-11-28 Chugai Pharmaceutical Co Ltd Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
DE69611288T2 (en) 1995-02-28 2001-07-19 Procter & Gamble Producing a non-carbonated beverage with improved microbial stability
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
MA24512A1 (en) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Method for preparation of useful anticoagulant agents in the treatment of thrombosis
CA2259163C (en) 1996-07-19 2004-07-06 Amgen Inc. Nt-3 and bdnf analogs having improved circulating life and/or absorption
CZ106299A3 (en) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies against protein related to human parathroidal hormone
JP3587664B2 (en) 1996-10-04 2004-11-10 中外製薬株式会社 Reshaped human anti-HM1.24 antibody
UA76934C2 (en) 1996-10-04 1999-12-29 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
JPH10165184A (en) 1996-12-16 1998-06-23 Tosoh Corp Antibody, gene and production of chimera antibody
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
JPH10256223A (en) 1997-03-11 1998-09-25 Super Silicon Kenkyusho:Kk Equipment for processing wafer chamfered part one by one
JP4228089B2 (en) 1997-03-11 2009-02-25 株式会社ニコン Overcurrent detection mechanism and electronic flash device using the same
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2761994B1 (en) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation of membrane receptors from extracellular baculoviruses
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (en) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt A process for the preparation of cell preparations for the immunization by means of heterologous intact bispecific and / or trispecific antibodies
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
WO1999018212A1 (en) 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
JPH11118775A (en) 1997-10-09 1999-04-30 Canon Inc Ultrasonic inspection device
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK1069185T3 (en) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humanized antibody to human tissue factor (TF) and method of constructing humanized antibody
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP3445153B2 (en) 1998-06-04 2003-09-08 富士通株式会社 Telephone number temporary use apparatus and method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
WO2000018806A1 (en) 1998-09-25 2000-04-06 Horst Lindhofer Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
CA2346264A1 (en) 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
CN1214043C (en) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 Humanized antibodies to gamma-interferon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
RU2236251C2 (en) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Methods for treatment of tumors and metastasis using combination of anti-angiogenic therapy and immunotherapy
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of immunological functional molecule.
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
AT411997B (en) 1999-09-14 2004-08-26 Baxter Ag Factor ix / factor ixa activating antibodies and antibody derivatives
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
JP3606132B2 (en) 1999-10-14 2005-01-05 Jfeエンジニアリング株式会社 Ultrasonic flaw detection method and apparatus
SE9903895D0 (en) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
MXPA02010801A (en) 2000-05-03 2004-09-06 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
AU6494601A (en) 2000-05-24 2001-12-03 Imclone Systems Inc Bispecific immunoglobulin-like antigen binding proteins and method of production
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
JP2002048867A (en) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd Acoustic survey device
AT364063T (en) 2000-09-12 2007-06-15 Union Carbide Chem Plastic Polymeric mixtures containing ethylene oxide copolymers
CN103333860B (en) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 Cells producing antibody compositions
WO2002040545A2 (en) 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
EP1250023A1 (en) 2001-04-11 2002-10-16 ALCATEL ALSTHOM COMPAGNIE GENERALE D'ELECTRICITE (abrégé: ALCATEL ALSTHOM) Provision of subscriber QoS guarantees to roaming subscribers
IL158376D0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
JP3642316B2 (en) 2001-06-15 2005-04-27 日本電気株式会社 Chemically amplified resist monomer, chemically amplified resist polymer, chemically amplified resist composition, pattern formation method
CN101240022B (en) 2001-06-22 2012-07-18 中外制药株式会社 Cell proliferation inhibitors containing anti-glypican 3 antibody
DK1517921T3 (en) 2002-06-28 2006-10-09 Domantis Ltd Immunoglobulin single variable antigen binding domains and double specific constructs thereof
DE10136273A1 (en) 2001-07-25 2003-02-13 Sabine Debuschewitz Molecular markers in hepatocellular carcinoma
PL217751B1 (en) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462369C (en) 2001-10-03 2009-12-22 Celator Technologies Inc. Compositions for delivery of drug combinations
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
JP4087098B2 (en) 2001-11-14 2008-05-14 株式会社東芝 Ultrasonic inspection equipment
DE60239013D1 (en) 2001-11-14 2011-03-03 Toshiba Kk Ultrasonograph with calculation of the breakdown of ultrasonic waves
US20050171339A1 (en) 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
AU2003216250A1 (en) 2002-02-11 2003-09-04 Genentech, Inc. Antibody variants with faster antigen association rates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
AU2003229191B2 (en) 2002-05-23 2009-07-30 Sunnybrook Health Sciences Centre Diagnosis of hepatocellular carcinoma
JP2004086862A (en) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc Apparatus, method and program for processing protein interaction information, and recording medium
WO2003107218A1 (en) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Interaction predicting device
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
JP4836451B2 (en) 2002-07-18 2011-12-14 メルス ベー ヴェー Recombinant production of antibody mixtures
JP3961359B2 (en) 2002-07-18 2007-08-22 株式会社東芝 Ultrasonic imaging device
US20040086979A1 (en) 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
TWI333958B (en) 2002-08-26 2010-12-01 Oncotherapy Science Inc
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004022597A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
CA2766627C (en) 2003-05-02 2019-12-03 Xencor, Inc. Optimized fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2562177T3 (en) 2002-09-27 2016-03-02 Xencor Inc. Optimized Fc variants and methods for their generation
DE60334141D1 (en) 2002-10-15 2010-10-21 Facet Biotech Corp CHANGE OF FcRn BINDING SAFFINITIES OR SERUM HALF TIMES OF ANTIBODIES BY MUTAGENESIS
DE602004021095D1 (en) 2003-01-21 2009-06-25 Chugai Pharmaceutical Co Ltd Method of screening the light chain of an antibody
WO2004068931A2 (en) 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20060228694A1 (en) 2003-04-02 2006-10-12 Janoff Andrew S Methods to individualize combination therapy
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US6921978B2 (en) 2003-05-08 2005-07-26 International Business Machines Corporation Method to generate porous organic dielectric
PT2272868E (en) 2003-06-05 2015-07-07 Genentech Inc Combination therapy for b cell disorders
JP4794301B2 (en) 2003-06-11 2011-10-19 中外製薬株式会社 Antibody production method
JP2005053541A (en) 2003-08-05 2005-03-03 Toppan Printing Co Ltd Laminate material for paper container, and paper container using the same
EP1671645A4 (en) 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd Remedy and detection drug for bile duct cancer
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1693448A4 (en) 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd Double specific antibodies substituting for functional protein
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
AU2004299833B2 (en) 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
CA2550996A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EA012872B1 (en) 2004-01-09 2009-12-30 Пфайзер Инк. Antibodies against MAdCAM
ITBO20040008U1 (en) 2004-02-03 2004-05-03 Tonazzi S R L The machine for filling and closing of tubes
JP4223981B2 (en) 2004-03-24 2009-02-12 学校法人東海大学 Formaldehyde detection material and manufacturing method thereof
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
US7691586B2 (en) 2004-04-28 2010-04-06 Perseus Proteomics Inc. Method for predicting and judging the recurrence of liver cancer after treating liver cancer
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp Antibodies against human interleukin-13 and uses thereof
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
DE102004032634A1 (en) 2004-07-06 2006-02-16 Sms Demag Ag Method and device for measuring and controlling the flatness and / or the strip tensions of a stainless steel strip or a stainless steel foil during cold rolling in a multi-roll stand, in particular in a 20-roll Sendizimir rolling mill
AT486610T (en) 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd ANTI-glypican-3 ANTIBODY
JP4331227B2 (en) 2004-07-09 2009-09-16 中外製薬株式会社 Anti-glypican 3 antibody
EP2213683B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant Fc regions
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
KR101300546B1 (en) 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 Adjuvant Therapy with the Use of Anti-Glypican 3 Antibody
EP1799718A1 (en) 2004-09-14 2007-06-27 National Institute for Biological Standards and Control (NIBSC) Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
NZ554940A (en) 2004-10-26 2010-04-30 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody having modified sugar chain
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
TW200635608A (en) 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Method of preparing antibody by use of cell having its fucose transporter function inhibited
CN101137673B (en) 2005-01-05 2013-12-04 比奥根艾迪克Ma公司 Cripto binding molecules
JP2008531060A (en) 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド A method for humanizing immunoglobulin variable regions via rational modification of complementarity determining residues
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
WO2006109592A1 (en) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke Anti-cd19 antibody therapy for autoimmune disease
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
JP2009500344A (en) 2005-07-01 2009-01-08 メディミューン,エルエルシー An integrated approach to manufacturing multidomain protein therapeutics
US8299252B2 (en) 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
WO2007030571A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Identification of targets and development of reagents for testing and molecular imaging of human disease
JP2007093274A (en) 2005-09-27 2007-04-12 Perseus Proteomics Inc Diagnostic method for cancer and therapeutic agent therefor
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US9102739B2 (en) 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
WO2007059111A2 (en) 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7723043B2 (en) 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
AU2007213028C1 (en) 2006-02-09 2011-05-19 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
WO2007099988A1 (en) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-FUCOSYLTRANSFERASE MUTANT AND USE THEREOF
JP2007256063A (en) 2006-03-23 2007-10-04 Seiko Epson Corp Display device and electronic equipment
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
JP2009539841A (en) 2006-06-06 2009-11-19 トラークス,インコーポレイテッド Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
DK2047863T3 (en) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Medicine for prevention or treatment of inflammatory diseases
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
JP4463793B2 (en) 2006-10-10 2010-05-19 浜松ホトニクス株式会社 Photodetector
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
CA2680237C (en) * 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2178921B1 (en) 2007-07-17 2016-01-06 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against glypican-3
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
PL3059246T3 (en) 2007-09-26 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BRPI0817637A2 (en) 2007-09-28 2015-09-08 Chugai Pharmaceutical Co Ltd anti-glipican-3 antibody having improved plasma kinetics
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent to attenuate a side effect comprising said antibody; method for treating or preventing liver cancer in a subject.
ES2400107T3 (en) 2007-10-22 2013-04-05 Merck Serono S.A. Single IFN-beta fused to an Fc fragment of mutated lgG
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI0909672B1 (en) 2008-03-17 2018-09-18 Chugai Pharmaceutical Co Ltd in vitro immunoassay method for detecting the presence of liver cancer cells in an individual, method for classifying liver cancer cells present in an individual, in vitro method for determining whether or not to administer an anticancer agent containing an anti-HIV antibody. glypican 3 to an individual, and in vitro method for determining a dose of an anticancer agent containing an anti-glycican 3 antibody in the treatment of liver cancer in an individual
PL2274008T3 (en) 2008-03-27 2014-07-31 Zymogenetics Inc Compositions and methods for inhibiting pdgfrbeta and vegf-a
BRPI0911431A2 (en) 2008-04-11 2015-10-06 Chugai Pharmaceutical Co Ltd antigen binding method that repeatedly bind to various antigen molecules
CN101377506A (en) 2008-04-16 2009-03-04 北京科美东雅生物技术有限公司 Monophosphoinositide proteoglycans-3 chemiluminescence immune analysis determination reagent kit and preparing method thereof
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BRPI0913366A2 (en) 2008-06-03 2015-11-24 Abbott Lab double variable domain immunoglobulins and their uses
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2015132478A (en) 2009-03-05 2015-12-10 Эббви Инк. Binding il-17 proteins
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
BRPI1010297A2 (en) 2009-04-07 2017-06-06 Roche Glycart Ag trivalent bispecific antibodies.
EP3505636A1 (en) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176868A1 (en) 2009-06-26 2012-02-28 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JP2011118775A (en) 2009-12-04 2011-06-16 Sony Corp Retrieval device, retrieval method, and program
EP2543727B1 (en) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
MX2012010481A (en) 2010-03-11 2012-10-09 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING.
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
KR20180135993A (en) 2010-04-20 2018-12-21 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
TW201742925A (en) 2010-04-23 2017-12-16 建南德克公司 Production of heteromultimeric proteins
JP6022444B2 (en) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション Heterodimeric protein and method for producing and purifying it
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
PT2647707T (en) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
KR20140014167A (en) 2011-02-25 2014-02-05 추가이 세이야쿠 가부시키가이샤 Fcγriib-specific fc antibody
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
CN103596985B (en) 2011-04-19 2016-06-08 美国政府(由卫生和人类服务部的部长所代表) The human monoclonal antibodies special to glypican-3 and purposes thereof
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
KR20140084249A (en) 2011-10-31 2014-07-04 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
MX358862B (en) 2011-11-04 2018-09-06 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain.
CA2889951A1 (en) 2012-11-02 2014-05-08 Zymeworks Inc. Crystal structures of heterodimeric fc domains
JP6226752B2 (en) 2012-02-09 2017-11-08 中外製薬株式会社 Modified Fc region of antibody
RU2014138586A (en) 2012-03-02 2016-04-20 Рош Гликарт Аг Prognostic biomarker for treating cancer with antibodies with an increased antibody-dependent cell cytotoxicity
DK2838918T3 (en) 2012-04-20 2019-08-12 Merus N V Methods and methods for preparing heterodimer ig-like molecules
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
CN104540852B (en) 2012-08-13 2018-10-02 瑞泽恩制药公司 Anti- PCSK9 antibody with pH- dependence binding characteristics
TR201815768T4 (en) * 2012-09-27 2018-11-21 Merus N V bispecific IgG antibodies in the T cell binding.
WO2014054804A1 (en) 2012-10-05 2014-04-10 協和発酵キリン株式会社 Heterodimeric protein composition
CN103833852A (en) * 2012-11-23 2014-06-04 上海市肿瘤研究所 Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen
TW201436805A (en) 2012-12-21 2014-10-01 Chugai Pharmaceutical Co Ltd Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
KR20160056940A (en) 2013-09-27 2016-05-20 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
JPWO2015046554A1 (en) 2013-09-30 2017-03-09 中外製薬株式会社 Method for producing antigen-binding molecule using modified helper phage
TW201613965A (en) 2014-04-07 2016-04-16 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3144388A4 (en) 2014-05-13 2018-05-02 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
SG10201800851XA (en) 2014-09-26 2018-03-28 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
RU2017123731A3 (en) 2014-12-19 2019-12-02
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy

Also Published As

Publication number Publication date
PE20170704A1 (en) 2017-06-14
JP5941235B1 (en) 2016-06-29
SG11201701119RA (en) 2017-03-30
CR20170124A (en) 2017-05-31
MX2017003503A (en) 2017-05-30
EA201790674A1 (en) 2017-08-31
JP2016196468A (en) 2016-11-24
TWI597290B (en) 2017-09-01
JP5941230B1 (en) 2016-06-29
JPWO2016047722A1 (en) 2017-04-27
JP2016166174A (en) 2016-09-15
CL2017000704A1 (en) 2017-12-01
PH12017500507A1 (en) 2017-08-30
CA2960650A1 (en) 2016-03-31
AU2015322543A1 (en) 2017-03-30
CN107002068A (en) 2017-08-01
KR20160135840A (en) 2016-11-28
US9975966B2 (en) 2018-05-22
TW201730209A (en) 2017-09-01
EP3199628A4 (en) 2018-06-06
KR101777077B1 (en) 2017-09-08
EP3199628A1 (en) 2017-08-02
WO2016047722A1 (en) 2016-03-31
IL250685D0 (en) 2017-04-30
RU2017113731A3 (en) 2019-09-20
US20170267783A1 (en) 2017-09-21
TW201619193A (en) 2016-06-01
KR20170104635A (en) 2017-09-15
RU2017113731A (en) 2018-10-22
US20180244805A1 (en) 2018-08-30
BR112017006061A2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
HK1217861A1 (en) Wifi-coordinated laa-lte
GB201419865D0 (en) Solution
HUE043227T2 (en) Combination
RU2017113731A (en) Inducing cytotoxicity therapeutic agent
AU358462S (en) Patient interface
GB201419094D0 (en) Anti-TIM-3-antibodies
GB201404893D0 (en) Selfie - Stick
HK1232137A1 (en) Therapeutic compounds and compositions
SG11201608616VA (en) Patient interfaces
GB201512365D0 (en) Novel therapy
GB201415569D0 (en) Therapeutic Compounds
AU361515S (en) Dishrack
HK1215864A1 (en) Cannula for catgut-embedding therapy
PL3142701T3 (en) New treatment
GB2528557B (en) Soundbar
IL263521D0 (en) Combination therapy
GB201403093D0 (en) Therapeutic compounds and their use
GB2529896B (en) Multirotor
HUE044950T2 (en) Schienenmesssystem
IL247073D0 (en) Combination
GB201412867D0 (en) Respiratory therapy devices
HUE042087T2 (en) Inhaler
ZA201702634B (en) Therapeutic agent delivery device
GB201509893D0 (en) Therapeutic agents
GB201405033D0 (en) Combination therapy